PubRank
Search
About
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Clinical Trial ID NCT01822509
PubWeight™ 14.40
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01822509
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
N Engl J Med
2016
1.88
2
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Oncoimmunology
2014
1.22
3
The targeting of immunosuppressive mechanisms in hematological malignancies.
Leukemia
2014
1.18
4
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Toxins (Basel)
2014
0.92
5
Novel immunotherapies for hematologic malignancies.
Immunol Rev
2015
0.90
6
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.
Bone Marrow Transplant
2015
0.89
7
Targeting the innate immune system as immunotherapy for acute myeloid leukemia.
Front Oncol
2015
0.89
8
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.
Clin Cancer Res
2014
0.83
9
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).
Ther Adv Hematol
2016
0.79
10
Immune Mechanisms in Myelodysplastic Syndrome.
Int J Mol Sci
2016
0.78
11
Immunotherapy strategies for multiple myeloma: the present and the future.
Immunotherapy
2013
0.76
12
Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
Biol Blood Marrow Transplant
2015
0.76
13
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.
J Natl Cancer Inst
2015
0.75
14
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
J Mol Med (Berl)
2015
0.75
15
Novel therapeutic options in Acute Myeloid Leukemia.
Leuk Res Rep
2016
0.75
16
Immunomodulatory drugs II: Immune Checkpoint Agents in Acute Leukemia.
Curr Drug Targets
2015
0.75
Next 100